Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors

scientific article published on 3 October 2007

Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JAC/DKM372
P698PubMed publication ID17913723

P50authorEva PovedaQ24934124
Vicente SorianoQ55277832
Juan González-LahozQ117269375
Angélica CorralQ117269384
P2093author name stringCarmen de Mendoza
Carolina Garrido
Julio Cobo
P433issue6
P407language of work or nameEnglishQ1860
P304page(s)1409-1410
P577publication date2007-10-03
P1433published inJournal of Antimicrobial ChemotherapyQ6294770
P1476titlePrevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors
P478volume60

Reverse relations

cites work (P2860)
Q36020992Antiretroviral drugs: critical issues and recent advances
Q36276790Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors
Q37252113Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults
Q33902540Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
Q33973857Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
Q37228725Etravirine for the treatment of HIV infection.
Q37405054Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection
Q37359827Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.
Q33558937Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients
Q35567828Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs
Q39599947Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
Q37306123Pharmacologic aspects of new antiretroviral drugs
Q83197990Pharmacologic aspects of new antiretroviral drugs
Q37288671The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance

Search more.